简
繁
EN
简
繁
EN
Home
Latest
Finance
IPO
ETF
Technology
Overseas
Research
HOME
·
02801.HK
iShares Core MSCI China Index ETF(02801.HK) rose 0.47% to HKD 25.520
Tags:
ETF
iShares Core MSCI China Index ETF
02801.HK
2026-05-06
iShares Core MSCI China Index ETF(02801.HK) rose 0.88% to HKD 25.300
Tags:
ETF
iShares Core MSCI China Index ETF
02801.HK
2026-04-29
iShares Core MSCI China Index ETF(02801.HK) fell 1.49% to HKD 25.040
Tags:
ETF
iShares Core MSCI China Index ETF
02801.HK
2026-04-28
iShares Core MSCI China Index ETF(02801.HK) fell 0.70%, quoted at HK$25.420
Tags:
ETF
iShares Core MSCI China Index ETF
02801.HK
2026-04-27
iShares Core MSCI China Index ETF (02801.HK) Falls 1.22% to HKD 25.860
Tags:
iShares Core MSCI China Index ETF
02801.HK
ETF
2026-04-22
iShares Core MSCI China Index ETF(02801.HK) Rises 1.95%, Intraday Turnover Rate 0.04%
Tags:
iShares Core MSCI China Index ETF
ETF
02801.HK
2026-04-16
Previous
1
2
Featured News
Finance
Marketingforce Management(02556.HK): Profit Forecast, Interim Revenue from AI Application Business Expected to Surge 112% to 134%
Finance
Hengrui Pharmaceuticals(01276.HK): Concentrated Solution for Injection HRS-8829 Receives Clinical Trial Approval Notice
Finance
MicroPort Scientific (00853.HK): Proposed Disposal of Controlling Stake in MicroPort Orthopedics (Shanghai) to Tinavi Medical
Finance
Renrui Human Resources(06919.HK): Non-executive Director Wang Xinjie Resigns; Gao Yunjie Appointed
Finance
Ubox Online (02429.HK): Full Circulation of H Shares Approved by HKEX
Finance
Chengdu Expressway (01785.HK): Signs Precast Concrete Component Procurement Contract for Chengdu-Wenjiang-Qionglai Expressway Expansion Project Worth Approximately RMB 234 Million
Finance
Prinx Chengshan (01809.HK): CEO Reshuffle – Che Baozhen Steps Down, Jiang Xizhou Appointed as President
Finance
Fameglow Holdings(03774.HK): Enters Technology Development Agreement with Sunseeker to Jointly Develop AI Anti-Aging Platform
Finance
Zhongtai Futures (01461.HK): Positive Profit Alert, Interim Net Profit Attributable to Parent Expected to Rise 190% to 210%
Finance
InnoCare Pharma Limited(09969.HK): Phase III Registrational Trial of Soficitinib (ICP-332) for Moderate-to-Severe Atopic Dermatitis Meets Primary Endpoint Successfully
Scan QR Code
Download App